Heavy! The results of the fourth batch of national elections were officially announced

Pharmaceutical Network February 4th, 118 Chinese pharmaceutical companies, 5 foreign enterprises Shanghai Sunshine Pharmaceutical Procurement Network officially released the fourth batch of national procurement results, the public release period is February 4 to February 7.
in accordance with the previous law, after the publicity period, the fourth batch of national election results will be confirmed.
that around May, the fourth batch of state mining is expected to land.
data show that the fourth batch of 45 drugs, all successfully purchased, involving hypertension, diabetes, digestive diseases, mental diseases, malignant tumors and other diseases.
the proposed drug price reduction of 52%, the highest reduction of 96%, for Qilu Pharmaceuticals injection of parrithib sodium (40 mg/bottle), the unit price of 3 pieces 5.
preliminary estimates, the fourth batch of drug collection is expected to save 12.4 billion yuan a year.
The fourth batch of state-owned mining a total of 152 enterprises to participate in the production of the proposed Chinese drug enterprises 118, the proposed selection of 158 products, enterprises to choose the proportion of 71%, compared with the previous batch, significantly improved.
a total of 21 foreign-funded companies participated in the bid, and in the end, five foreign companies were selected for the competition: Sanofi's ammonia-based pills (0.2g x 20 pieces); Than the propofol medium/long chain fat emulsion (0.2g x 5), Fessenyuskabi this time with 49.3 yuan in the same group of the lowest price, this price is even lower than Yangzijiang, Jiangsu Yingke and four Kawakoren; Sashi's Losolofen sodium tablets (60mg x 20 pieces) are to be selected for $5.52; Aurobindo Pharma Limited's vitolazole intestinal tablets (40mg x intestinal tablets) are to be selected for $5.52 30 pieces) at a center price of 19.86 yuan, and HEXAL AG 'Sandoz Private Limited's Voliconazole tablets (200mg x 30 pieces) at 1044 yuan.
It is worth noting that, according to Milnet data, of the 45 varieties collected in the fourth batch, 21 have original research manufacturers, of which 11 have a market share of more than 50% in the end-of-market competition pattern of China's public medical institutions in 2019.
e.g. Novo Nordisk's Reglinay oral regular release dosage form (market share 58.28%), AstraZeneone's AstraZeneta oral regular release dosage form (market share 82.16%), Pfizer's Parry Seb injections (market share 60.59%), Fessenyuscabi propofol medium/long chain fat emulsions (market share 61.92%), Novartis prolystamin chlorpyrifos I. oral regular release type (100% market share), AstraZenecom's tegrelo oral regular release dosage form (market share 97.64%), Schweija's Gretzette resuspension control agent type (79.29%), 13th A total of left oxyfluorosa star oral normal release agent type (market share of 55.27%), etc. , of which the oxysatan ammonia chloride level I. oral normal release agent type, tegrelo oral normal release agent type is basically exclusive by the original research manufacturers.
It is not difficult to see that, with the landing of the fourth batch of national mining, the above-mentioned varieties, in addition to propofol / long-chain fat emulsion, the market share of the remaining pharmaceutical raw products in the fourth batch of national procurement period, will be divided by other selected domestic generic pharmaceutical enterprises.
Up to now, the normalization of drug collection and collection by the state organization is almost certain, the national harvest through the volume of price exchange, compression of drug price moisture, to achieve generic drugs for the original research drug in-hospital replacement, the original research drug companies began to change strategies, strategic abandonment of the national market, relying on brand advantages to the product to retail terminals and other out-of-hospital markets, and focus on the layout of innovative drugs in-house development, and these large use of clinical commonly used varieties of in-house shares will gradually occupy by domestic pharmaceutical companies.
pharmaceutical enterprises, accounting for more than half of the fourth batch of national products selected in the proposed, listed companies, foreign-funded enterprises, top 100 enterprises and other companies accounted for 62% of the products.
According to previous statistics, in the fourth batch of national mining, there are 12 enterprises with 3 or more over-evaluated varieties, Qilu Pharmaceuticals, Yangzijiang Pharmaceuticals are leading by 7 over-rated varieties, China Biopharmaceuticals, Stone Pharmaceuticals Group involved in the over-evaluation Varieties are 6, 5, Howson Pharmaceuticals, Colum Pharmaceuticals, Dongsun Pharmaceuticals and Fosun Pharma have 4 over-rated varieties in the column, Bett Pharmaceuticals, Baiao Pharmaceuticals, Fuyuan Pharmaceuticals and Hengrui Pharmaceuticals each have 3 varieties involved.
in the previous national mining outstanding Performance of Qilu, in the fourth batch of mining involving 7 varieties, respectively - ammonia pills, injection of parrisheb sodium, injection of boron titzomi, Pribarin capsules, hydrochloric acid tebifen tablets and injection of bival reeds, hydrochloric acid Prakso tablets.
According to the results of the fourth batch of national selection, Qilu Pharmaceuticals finally proposed to select six varieties, namely: injection with parrishib sodium, injection of boron tazizomi, hydrochloric acid Praxo tablets, Pribarin capsules, hydrochloric acid tebifen tablets, injection of bival reed.
, Qilu Pharmaceuticals' hydrochloric acid Prakso tablets, Pribarin capsules and injection-based bivaldis were approved for sale in 2020, the successful bid, is expected to quickly open the market.
Yangzijiang Pharmaceuticals to choose the varieties are: propofol medium / long-chain fat emulsion, doso-tea-alkali injection, chloretamine tablets, injection with parexib sodium, injection with sodium palatine, sodium glazate drop eye drops 6.
Among them, dosso-tea-alkali injections, sodium glazate eye drops were approved for the market in 2020, propofol medium/long-chain fat emulsions were approved in 2021, and are also expected to enter the market rapidly through the fourth batch of national harvest.
Koren Pharmaceuticals performed well this time, Ngle net tablets, propofol medium/ long chain fat emulsion, injection with parrixib sodium, hydrochloric acid ammonia bromoso injection 4 drugs to be the fourth batch of national drug collection.
one of the chinese biopharmaceuticals actively participating in the proposed selection of varieties are: Eso meprazole magnesium intestinal capsules, Engle net tablets, enturabinofove tablets, kagle net tablets, injection boron zomi, tigrillo tablets 6.
addition, Dongsun Holdings subsidiary hydrochloric acid lositin intestinal capsules, left oxyfluorosa star tablets and other 4 drugs to participate in the national drug centralized procurement and confirm the proposed selection.
Biologics, Chinese medicine collection on the road according to Henyep Securities statistics, review the past three batches of national drug collection, involving a total of 112 varieties, the average decline in selected products reached 54%, by 2020 the actual procurement volume has reached 2.4 times the agreed procurement volume, saving costs overall more than 100 billion yuan.
, in accordance with the requirements of the normal institutionalization of drug centralized procurement, the scope of centralized drug procurement by state organizations will continue to expand in the future.
On the occasion of the forthcoming implementation of the fourth batch of collection, the General Office of the State Council issued the Opinions on Promoting the Normalization and Institutionalization of the Purchase of Drug Concentrated Bands to Further Clarify the Normalization Mechanism of Drug Collection.
document clearly focuses on the basic medical insurance drug catalog of large quantities, high procurement amount of drugs into the procurement scope, and gradually cover the domestic market clinically necessary, reliable quality of all types of drugs, so that should be harvested.
In addition to qualified drugs, the document also proposed to actively explore the "orphan drugs", shortage of drugs suitable procurement methods, you can see that as long as the clinical needs of the product, the future will be possible to be included in the scope of collection.
expected that in the future for the varieties that have not yet been consistently evaluated, it will also be possible to try to collect.
it is worth mentioning that this document proposes to explore the integration of different generic drugs with similar allergies or functional treatments for centralized volume procurement.
Henyep Securities analysis pointed out that, on the one hand, combined with the previous monitoring of collected varieties of alternative drugs, the promotion of this policy will likely further standardize the actual use of collected varieties at the clinical end;
At present, it is assumed that the inclusion of large varieties of biosynthetes and Chinese medicines in the harvest will gradually be on the agenda, and it is expected that the rules will be more optimized and the quality will be more in line with the attributes of the corresponding drugs themselves.
can be said that, with the normalization and regularization of drug collection by state organizations, more varieties have been incorporated into the national harvest has been basically no suspense.
the results table of the proposed national centralized drug procurement